{"id":"W2603868241","doi":"10.1200/jco.2012.30.15_suppl.e14706","title":"Multistage phase II design for mixed tumor response and time-to-event endpoints: An application for screening new drugs in hepatocellular carcinoma (HCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Surrogate endpoint; Oncology; Internal medicine; Early stopping; Progression-free survival; Hepatocellular carcinoma; Hazard ratio; Phases of clinical research; Randomized controlled trial; Clinical trial; Overall survival; Confidence interval; Machine learning","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06279633,0.0002429228,0.002210897,0.0001950682,0.00009872671,0.00001792123,0.0003634542,0.0004367276,0.00007621184],"category_scores_gemma":[0.2861799,0.0002035412,0.0004090562,0.0001519647,0.0001515433,0.0001945437,0.0001182811,0.0006030297,0.00000894493],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000146487,"about_ca_system_score_gemma":0.0006561793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007383981,"about_ca_topic_score_gemma":0.000002387334,"domain_scores_codex":[0.9892331,0.004752619,0.004757484,0.0003863767,0.0003329532,0.000537471],"domain_scores_gemma":[0.8088386,0.1871846,0.002306592,0.0003190865,0.0003222342,0.001028921],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.1564384,0.01101838,0.003334886,0.0001798121,0.0002761291,0.00006269009,0.001317287,0.00003681287,0.008010218,0.005982799,0.01219994,0.8011426],"study_design_scores_gemma":[0.1125447,0.1156442,0.01611668,0.0004434483,0.001602119,0.000177209,0.0008020112,0.08392201,0.008252286,0.5724588,0.08681631,0.001220173],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"methods","genre_scores_codex":[0.4068635,0.00004961679,0.5898266,0.001330387,0.0003618071,0.001512828,0.000036264,0.00001067468,0.000008363799],"genre_scores_gemma":[0.2696607,0.000005334221,0.7282476,0.0005423073,0.001236144,0.0001035724,0.000001613851,0.00004279377,0.0001598755],"genre_candidate":"methods","genre_consensus":"methods","teacher_disagreement_score":0.7999225,"threshold_uncertainty_score":0.9650484,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.590656214930436,"score_gpt":0.6152416354378769,"score_spread":0.02458542050744095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}